IBD overlap changes colorectal cancer screening for rare subtypes

Written by The Life Science Feed Editorial Team · Edited by Mara Voss

Colorectal carcinoma (CRC) screening protocols generally follow established guidelines, but a new analysis of rare CRC subtypes reveals a critical overlap with inflammatory bowel disease (IBD) that significantly impacts patient prognosis. This connection, particularly strong for enteroblastic CRC, demands a re-evaluation of current screening and management strategies for patients with IBD. The findings, published in American Journal of Surgical Pathology, highlight the aggressive nature of these less common cancers and the prognostic weight of co-occurring IBD.1

KEY TAKEAWAYS

- The Pivot: Inflammatory bowel disease significantly worsens recurrence-free survival in rare colorectal carcinoma subtypes, particularly enteroblastic CRC.
- The Data: IBD significantly worsened recurrence-free survival on multivariate analysis, with enteroblastic cases most likely to recur (54%, P=.015).
- The Action: Clinicians should consider more intensive or tailored colorectal cancer screening for IBD patients, especially those with enteroblastic or hepatoid CRC risk factors.

Colorectal carcinoma (CRC) presents in various forms, but three rare subtypes, enteroblastic, hepatoid, and clear cell carcinomas, have historically posed diagnostic challenges due to their morphological and immunohistochemical (IHC) similarities. These subtypes, while uncommon, carry distinct clinical correlations and outcomes that warrant precise identification. A recent study sought to clarify these distinctions and assess their clinical impact, particularly in the context of inflammatory bowel disease (IBD).1

The investigation involved a retrospective analysis of 37 CRCs suspected to represent these rare subtypes. Researchers circulated provisional diagnostic criteria, along with photomicrographs and IHC data, among a panel of authors to achieve consensus classifications. This methodology aimed to mitigate interobserver variability, a known issue in the diagnosis of these histologically ambiguous cancers. The patient cohort included individuals with varying stages of disease at presentation, providing a comprehensive view of the natural history of these aggressive malignancies.1

Defining the Rare Subtypes

The study established a plurality consensus for classifying the 37 cases: 13 were identified as enteroblastic, 6 as hepatoid, and 18 as clear cell carcinomas. Achieving unanimous agreement proved difficult, occurring in only 18% of cases (3 clear cell, 3 hepatoid). This highlights the inherent diagnostic complexity, even among experienced pathologists. Interobserver analysis yielded a mean pairwise Cohen ℅f 0.63 (range: 0.32 to 0.91), indicating moderate agreement overall, with the

hepatoid subtype eliciting the strongest consensus among the panel.1

Clear cell areas frequently intermixed with conventional CRC components (P<.001), suggesting a potential continuum or a clear cell change within more common CRC types. This observation complicates diagnosis further, as it implies that these rare subtypes may not always present as pure entities. The study's focus on refining diagnostic criteria is critical, given the potential for misclassification and its downstream effects on patient management.1

The IBD Connection and Prognostic Impact

A striking finding was the prevalence of inflammatory bowel disease among these patients. Seven of the 37 patients (20%) had IBD, with most of these cases linked to enteroblastic CRC. This association is not merely incidental; multivariate analysis revealed that IBD significantly worsened recurrence-free survival. This means that for patients presenting with these rare CRC subtypes, a co-diagnosis of IBD carries a substantial negative prognostic weight, independent of other factors.1

The clinical implications for patients with IBD are considerable. Given that IBD is a known risk factor for conventional CRC, this study underscores an even more aggressive trajectory when these specific rare subtypes develop. GPs and gastroenterologists managing IBD patients should be acutely aware of this heightened risk, particularly if there are any atypical presentations or rapid progression of symptoms. The role of bowel ultrasound in IBD monitoring may need to be re-evaluated in this context, potentially leading to earlier or more frequent endoscopic surveillance.1

Aggressive Disease Course and Metastasis

These rare CRC subtypes demonstrated an aggressive clinical course. At presentation, 23 of 34 patients (68%) had nodal metastasis, and 12 (32%) had distant metastasis. Liver metastasis was particularly common among those with distant spread. The median recurrence-free survival was a mere 17 months. Enteroblastic cases were the most prone to recurrence, with 54% of these patients experiencing disease recurrence (P=.015). This high rate of recurrence, coupled with early metastasis, paints a grim picture for these patients.1

The median follow-up length was 27 months, during which 14 patients (40%) died of their disease. This mortality was distributed across the subtypes: 7 enteroblastic, 4 hepatoid, and 3 clear cell CRC. Distant metastasis at presentation significantly worsened both recurrence-free and overall survival on multivariate analysis. This reinforces the need for early detection and aggressive management strategies, as the presence of distant spread is a powerful predictor of poor outcomes.1

Genetic Market and Biomarker Potential

The study also explored the mutational market of these tumors. Mutations were identified in TP53 (n=8), APC (n=3), FBXW7 (n=2), and KRAS (n=1). While the sample size for genetic analysis was small, these findings align with common CRC oncogenic pathways, suggesting that despite their rare histology, these tumors share some molecular drivers with conventional CRC. But the specific prevalence and prognostic significance of these mutations within these rare subtypes warrant further investigation in larger cohorts.1

The identification of specific molecular markers could aid in both diagnosis and prognostication. For instance, a separate study explored quantitative proteomic and glycoproteomic analysis, identifying CLCA1, FBN1, and FGB as potential biomarkers for ulcerative colitis.2 While that study focused on ulcerative colitis specifically, the broader search for biomarkers in inflammatory conditions and associated cancers is relevant. The distinct immunophenotype observed

in enteroblastic and hepatoid CRCs in the current study also suggests that IHC markers could be refined to improve diagnostic accuracy and potentially guide targeted therapies.1

Challenges in Diagnosis and Future Directions

The significant interobserver variability in diagnosis, particularly for clear cell and enteroblastic subtypes, underscores a critical limitation in current pathological practice. The provisional criteria used in this study, while a step forward, require further refinement and validation. Without consistent and reliable diagnostic criteria, comparing outcomes across studies and implementing standardized treatment protocols remains challenging. The question of how various factors influence colorectal cancer survival, including diagnostic precision, remains an active area of research.1,3

The study's relatively small sample size (N=37) is an obvious caveat, inherent to the rarity of these CRC subtypes. While the detailed analysis of each case provides valuable insights, the statistical power to detect subtle differences or interactions may be limited. Larger, multi-institutional collaborations are necessary to validate these findings and develop more robust diagnostic and prognostic models. The strong association between IBD and worsened recurrence-free survival, however, is a clear signal that warrants immediate clinical attention, regardless of the sample size.1

The overlap between these rare CRC subtypes and IBD necessitates a more integrated approach to patient care. Gastroenterologists and oncologists must collaborate closely to ensure that IBD patients are adequately screened for CRC, and that any detected lesions are meticulously characterized. The aggressive nature of enteroblastic and hepatoid CRCs, coupled with the prognostic impact of IBD, means that a proactive and vigilant approach is paramount. The Oxford Handbook of Oncology (4th ed) provides a concise reference for managing such complex cancer cases, offering practical guidance for clinicians.1

The study also did not examine the specific mechanisms by which IBD exacerbates the prognosis of these rare CRC subtypes. Is it chronic inflammation driving more aggressive tumor biology, or are there shared genetic predispositions? Future research should explore these mechanistic questions to identify potential therapeutic targets. Understanding the molecular relationship between IBD and these specific CRC histologies could unlock novel treatment strategies beyond conventional chemotherapy.1

Finally, the study did not explore the impact of different IBD therapies on CRC risk or prognosis in this specific population. Given the evolving guidelines of IBD management, understanding how biologics or small molecules might influence the development or progression of these rare CRCs is a critical unanswered question. This gap matters, as many IBD patients are on long-term immunomodulatory therapies, which could theoretically influence cancer biology.1

> **CLINICAL IMPLICATIONS**
>
> The finding that inflammatory bowel disease significantly worsens recurrence-free survival in rare colorectal carcinoma subtypes, particularly enteroblastic CRC, should immediately prompt a re-evaluation of screening strategies for IBD patients. Current guidelines for CRC surveillance in IBD may not adequately capture the aggressive nature and distinct prognostic implications of these less common histologies. GPs and gastroenterologists must consider this heightened risk, moving beyond a 'one-size-fits-all' approach to CRC screening in this vulnerable population.
>
> For patients with IBD, this means a more vigilant approach to any new or changing gastrointestinal symptoms. The strong association between IBD and enteroblastic CRC, coupled with the high rates of nodal and distant

metastasis, demands earlier and potentially more frequent endoscopic surveillance. It is no longer sufficient to treat IBD as a general risk factor; the specific histological subtype of any detected CRC must inform subsequent management and prognostic discussions.

The diagnostic challenges highlighted by the interobserver variability in classifying these rare CRCs also have direct implications for pathology services. Pathologists need refined criteria and potentially specialized training to accurately identify enteroblastic, hepatoid, and clear cell carcinomas. Misdiagnosis can lead to inappropriate staging and suboptimal treatment, directly impacting patient outcomes. This calls for a concerted effort to standardize diagnostic protocols across institutions.

The aggressive clinical course and poor survival observed in these patients, especially those with co-occurring IBD, underscore an urgent unmet need for more effective therapies. The identified mutations in TP53, APC, FBXW7, and KRAS offer potential avenues for targeted treatments, but these must be explored within the context of these rare histologies. Without improved diagnostic precision and tailored therapeutic approaches, these patients will continue to face a disproportionately high burden of disease.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Khan F, Polydorides AD, Paulsen JD. Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer. Am J Surg Pathol 2026.
2. 2. Wang X, Bo S, Li Q. Quantitative proteomic and glycoproteomic analysis identifies CLCA1, FBN1, and FGB as potential biomarkers for ulcerative colitis. RSC Adv 2025.
3. 3. Khan S, Gupta A, Agarwal A. Beyond the brain: The colorectal impact of Parkinson's disease. J Parkinsons Dis 2025.

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED